Akebia Therapeutics (AKBA) Price & Analysis

Compare

1,480 Followers

AKBA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.07 - $4.08

Previous CloseN/A

Volume5.66M

Average Volume (3M)3.26M

Market Cap

$977.01M

Enterprise Value$556.68M

Total Cash (Recent Filing)$113.37M

Total Debt (Recent Filing)$54.15M

Price to Earnings (P/E)―

Beta1.38

Next Earnings

Nov 06, 2025

EPS Estimate

-0.03

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.00

Shares Outstanding262,635,830

10 Day Avg. Volume3,231,938

30 Day Avg. Volume3,263,365

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.57

Enterprise Value/Revenue3.01

Enterprise Value/Gross Profit4.44

Enterprise Value/Ebitda94.27

Forecast

1Y Price Target

$7.00

Price Target Upside88.17% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Financial PerformanceAkebia reported total revenues of approximately $57 million, which were significantly above consensus and management's estimates, driven by a strong start for the Vafseo product launch.

Partnership And Market ExpansionThe EMA's Committee for Medicinal Products for Human Use issued a positive opinion recommending that the European Commission approve XOANACYL for treating adult CKD patients, increasing confidence in market expansion.

Product UptakeApproved product VAFSEO, indicated for the treatment of anemia due to chronic kidney disease in adults receiving dialysis, continues to gain uptake among dialysis organizations.

Bears Say

Generic CompetitionAuryxia is forecast to face generic entry post-March 2025 IP expiry, which could lead to a decline, despite strategic contracting efforts.

Akebia Therapeutics News

Akebia reports Q2 EPS 0c vs (4c) last year

Reports Q2 revenue $62.472M, consensus $47.24M. “Vafseo U.S. product launch momentum builds as we continued to add new...

21h ago

AKBA

Akebia initiates post-marketing study to identify benefits of Vafseo

Akebia (AKBA) Therapeutics announced the initiation of a post-marketing study to identify additional potential benefits of Vafseo. The...

4d ago

AKBA

Akebia Therapeutics Reports Strong Q2 2025 Growth

Akebia Therapeutics ( ($AKBA) ) has released its Q2 earnings. Here is a breakdown of the information Akebia...

3h ago

AKBA

Strategic Partnerships and Clinical Trials Propel Akebia Therapeutics’ Growth Potential

Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on AKBA stock, giving a Buy rating on...

2d ago

AKBA

Akebia Therapeutics (AKBA) Q2 Earnings Cheat Sheet

Akebia Therapeutics (AKBA) is scheduled to report 2nd quarter earnings on 08/07/2025, before the market opens. Regarding Q2...

3d ago

AKBA

Akebia Therapeutics Approves Stock Plan Amendment at Meeting

Akebia Therapeutics ( ($AKBA) ) has shared an announcement. At its Annual Meeting on June 10, 2025, Akebia...

2M ago

AKBA

International Paper, ImmunityBio, Agenus, Akebia, Apple: Trending by Analysts

Analysts are intrested in these 5 stocks: ( ($IP) ), ( ($IBRX) ), ( ($AGEN) ), ( ($AKBA)...

2M ago

AAPL

Akebia announces JASN published analysis from vadadustat phase 3 program

Akebia (AKBA) Therapeutics announced that the Journal of the American Society of Nephrology, JASN, has published pre-specified analyses...

2M ago

AKBA

Buy Rating for Akebia Therapeutics Driven by VAFSEO’s Market Potential in CKD Anemia

Matthew Caufield, an analyst from H.C. Wainwright, has initiated a new Buy rating on Akebia Therapeutics (AKBA). Matthew...

2M ago

AKBA

Akebia assumed with a Buy at H.C. Wainwright

H.C. Wainwright analyst Matthew Caufield assumed coverage of Akebia (AKBA) with a Buy rating and $8 price target...

2M ago

AKBA

Akebia Therapeutics’ Growth Potential Driven by Vafseo’s Market Expansion and Upcoming VALOR Trial

Leerink Partners analyst Roanna Ruiz maintained a Buy rating on Akebia Therapeutics (AKBA – Research Report) yesterday and...

2M ago

AKBA

Akebia Therapeutics: Strong Financial Performance and Promising Growth Prospects Drive Buy Rating

In a report released on May 9, Roanna Ruiz from Leerink Partners reiterated a Buy rating on Akebia...

3M ago

AKBA

Akebia Therapeutics Reports Strong Q1 2025 Performance

Akebia Therapeutics ( ($AKBA) ) has released its Q1 earnings. Here is a breakdown of the information Akebia...

3M ago

AKBA

Akebia Therapeutics Reports Strong Vafseo Launch Success

Akebia Therapeutics (($AKBA)) has held its Q1 earnings call. Read on for the main highlights of the call....

3M ago

AKBA

AKBA FAQ

What was Akebia Therapeutics’s price range in the past 12 months?

Akebia Therapeutics lowest stock price was $1.07 and its highest was $4.08 in the past 12 months.

What is Akebia Therapeutics’s market cap?

Akebia Therapeutics’s market cap is $977.01M.

When is Akebia Therapeutics’s upcoming earnings report date?

Akebia Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 90 days.

How were Akebia Therapeutics’s earnings last quarter?

Akebia Therapeutics released its earnings results on Aug 07, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.015 by $0.015.

Is Akebia Therapeutics overvalued?

According to Wall Street analysts Akebia Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Akebia Therapeutics pay dividends?

Akebia Therapeutics does not currently pay dividends.

What is Akebia Therapeutics’s EPS estimate?

Akebia Therapeutics’s EPS estimate is -0.03.

How many shares outstanding does Akebia Therapeutics have?

Akebia Therapeutics has 262,635,830 shares outstanding.

What happened to Akebia Therapeutics’s price movement after its last earnings report?

Akebia Therapeutics reported an EPS of $0 in its last earnings report, beating expectations of -$0.015. Following the earnings report the stock price went up 6.504%.

Which hedge fund is a major shareholder of Akebia Therapeutics?

Currently, no hedge funds are holding shares in AKBA

Akebia Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

91.25%

Trailing 12-Months

Asset Growth

37.57%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Akebia Therapeutics

Akebia Therapeutics, Inc. (AKBA) is a biopharmaceutical company that focuses on the development and commercialization of therapeutics for patients with kidney disease. The company operates primarily in the healthcare sector, targeting the nephrology space. Akebia's core products include vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to treat anemia due to chronic kidney disease (CKD).

Akebia Therapeutics (AKBA) Earnings & Revenues

Historic Earnings Reports

AKBA Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call demonstrates strong early success with Vafseo's launch, exceeding expectations and showing promising trends in prescriptions and financials. While there are concerns about potential generic competition for Auryxia and slower integration with large dialysis organizations, the overall performance and future prospects are encouraging.View all AKBA earnings summaries

AKBA Stock 12 Month Forecast

Average Price Target

$7.00

▲(88.17% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","9":"$9","-1":"-$1","1.5":"$1.5","6.5":"$6.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.5,4,6.5,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.57,3.9107692307692306,4.251538461538462,4.592307692307692,4.933076923076923,5.273846153846153,5.614615384615385,5.955384615384615,6.296153846153846,6.636923076923077,6.977692307692307,7.318461538461538,7.659230769230769,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.57,3.833846153846154,4.0976923076923075,4.361538461538461,4.625384615384615,4.889230769230769,5.153076923076923,5.4169230769230765,5.680769230769231,5.944615384615384,6.208461538461538,6.472307692307693,6.7361538461538455,{"y":7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.57,3.756923076923077,3.943846153846154,4.13076923076923,4.317692307692307,4.504615384615384,4.691538461538461,4.878461538461538,5.065384615384615,5.252307692307692,5.439230769230769,5.626153846153846,5.813076923076923,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.24,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.99,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.55,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.28,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.69,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.13,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.9,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.85,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.39,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.25,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.57,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >